Strategy

MBC Pharma's approach is to use its technical expertise, patented intellectual property and know how in preclinical development to optimize and develop compounds to treat bone diseases such as osteoporosis and metastatic bone disease. This approach can be summarized as the following three goals:

1. MBC will establish the therapeutic potential of our vitamin B6-aminobisphosphonate family of compounds as new therapies for osteoporosis, osteopenia and/or complications arising from metastatic bone disease.
2. MBC will expand and gain further insight into the potential of our patented chemotherapy-bisphosphonate conjugates as therapeutic modalities for direct treatment of metastatic tumors such as multiple myeloma, breast, prostate and lung cancers.
3. MBC will continue to pursue applications of our intellectual property in new disease areas or in new approaches to the above disease areas.

We are engaged in a number of productive research collaborations with academic and medical institutions, as well as with private sector contract research organizations. A long running collaboration with the Mayo Clinic has resulted in three STTR grant awards from the National Institutes of Health. Pending grants applications have been submitted to the NIH and our strategy includes continued pursuit of STTR and SBIR funding to leverage privately raised Company funds. Presently, our seed-stage activities are fully funded and the Company is raising money to assure the continued success of our preclinical development initiatives, to expand the scope of those programs and to add shareholder value.

  MBC Pharma is currently seeking pharmaceutical or biotechnology company partners for our osteoporosis and oncology programs. Interested parties may contact us at license@mbcpharma.com for more information.